Evidence map›Paper›PMID 36835493›Full record

ReviewInternational journal of molecular sciences2023

Yasuyo Ohguchi, Hiroto Ohguchi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Karyotype evolution of multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2026
    Article
  3. [Value of gene mutation in the prognosis and treatment of multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Review
  4. Built differently or defective: can RNA exosomopathies cause ribosome heterogeneity?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Multiple myeloma-associatedBlood neoplasia · 2024
    Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yasuyo OhguchiDivision of Disease Epigenetics, Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.
Hiroto OhguchiDivision of Disease Epigenetics, Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.ORCID 0000-0001-8461-7398
Kumamoto University · JP

Funding

Japan Society for the Promotion of Science 20K08734Japan Society for the Promotion of Science JP 16H06276 (AdAMS)the Friends of Leukemia Research Fund NAthe SGH Foundation NAthe Shinnihon Foundation NA
6 · The paper itself

Abstract

Recent studies have revealed the genetic aberrations involved in the initiation and progression of various cancers, including multiple myeloma (MM), via next-generation sequencing analysis. Notably,

Indexed as

Exosome Multienzyme Ribonuclease ComplexMultiple MyelomaGenomic InstabilityHumansMutationRNADIS3 protein, humanExosome Multienzyme Ribonuclease ComplexRNADIS3genetic eventshematopoiesismultiple myelomaRNA exosome

Identifiers

PMID36835493
PMCPMC9958658
OpenAlexW4321374445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.